Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal C · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Meningococcal C | BIOLOGICAL | - |
| DTP/Hib | BIOLOGICAL | - |
Inclusion Criteria: * Healthy infants 7-10 weeks of age eligible to receive routine immunization
Meningococcal C is a vaccine being studied for the prevention of meningitis and meningococcal disease. It is currently in Phase 2 clinical development and is being evaluated in infants as young as 7 weeks of age. The vaccine is designed to protect against infections caused by Neisseria meningitidis serogroup C.
Meningococcal C is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the safety and tolerability of this vaccine in the target population.
Meningococcal C is currently in Phase 2 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. The Phase 2 trial has been completed, and the vaccine is being studied for its safety and tolerability in infants.
Meningococcal C has one completed Phase 2 clinical trial registered under NCT00314041, titled "Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants." This trial enrolled 240 participants, was randomized and double-blind, and included healthy volunteers. The study was conducted to assess the vaccine's tolerance in infants.
Meningococcal C is a conjugate vaccine, as indicated by the clinical trial title which refers to "Conjugate Meningococcal C Vaccine." Conjugate vaccines are designed to enhance the immune response, particularly in young children. This vaccine specifically targets serogroup C of Neisseria meningitidis, a common cause of meningococcal disease.